Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments

This article was originally published in The Tan Sheet

Executive Summary

OTC switch product sales are estimated to grow at a compounded annual growth rate of 5% by 2019, with opportunities likely emerging in bladder control for women and sleep aids, according to Kline Market Research. But asthma drugs and statins are not likely to debut OTC soon, notes analyst Laura Mahecha.

You may also be interested in...



Benefit From OTC Switches Supported In Study Of PPIs' Outpatient Impact

Proton pump inhibitor OTC switches since 2003 had a profound and sustained impact on outpatient health care visits – illustrating the potential for other switches to benefit US health care, a recent study suggests.

Benefit From OTC Switches Supported In Study Of PPIs' Outpatient Impact

Proton pump inhibitor OTC switches since 2003 had a profound and sustained impact on outpatient health care visits – illustrating the potential for other switches to benefit US health care, a recent study suggests.

Dermatology OTC Switches Loom Next For Consumer Health Growth

Dermatology OTC switch products for acne, eczema and psoriasis are likely to emerge, says Kline analyst Laura Mahecha. Switches, the return of recalled OTC brands and market consolidation drove a 4.2% increase for the US consumer health market in 2015.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel